leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Leukemias are common worldwide.Wilms' tumor1 (WT1) protein is highly expressed in leukemic blast cells of myeloid and lymphoid origin.
|
16491848 |
2006 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Wilms tumor protein 1 (WT1) is a transcription factor overexpressed in several types of leukemia and solid tumors.
|
16990779 |
2006 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
18559874 |
2008 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
WT1 gene expression has been proposed as a useful marker of minimal residual disease in leukaemia.
|
19650884 |
2009 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Wilms tumor 1 (WT1) oncoprotein is an intracellular oncogenic transcription factor which is barely expressed in normal adult tissues but over expressed in a variety of leukemias and solid cancers.
|
31408937 |
2019 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner.
|
15845894 |
2005 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Due to its immunogenicity and overexpression concomitant with leukemia progression, Wilms tumor protein 1 (WT1) is of particular interest for immunotherapy of AML relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
|
27896368 |
2017 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the wild-type WT1 gene is highly expressed in leukemic blast cells of myeloid and lymphoid origin, and thus, WT1 messenger RNA provides a novel tumor marker for detection of minimal residual disease of leukemias and for monitoring disease progression of myelodysplastic syndromes.
|
11372729 |
2001 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, vaccination of C57BL/6 mice with Ad-tWT1 generated WT1-specific cell-mediated and humoral immune responses and conferred protection against challenge with the leukemia cell line, mWT1-C1498.
|
19351755 |
2009 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression.
|
10995011 |
2000 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Leukemic cells from seventy patients with various types of human leukemias were examined for expression of the WT1 gene, the Wilms' tumor gene located at chromosome 11p13.
|
1317488 |
1992 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Minimal residual disease (MRD) of leukemia can be detected at frequencies as low as 1 in 10(3) to 10(4) normal bone marrow (BM) cells and 1 in 10(5) normal peripheral blood (PB) cells by means of the quantitation of expression levels of the WT1 gene using reverse transcriptase-polymerase chain reaction (RT-PCR).
|
9669676 |
1998 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Most cases of leukemia show hTERT and WT1 gene overexpression.
|
21314483 |
2011 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia.
|
15223639 |
2004 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the WT1 gene in sporadic childhood leukaemia.
|
9001425 |
1997 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Of these, 230 were monitored concurrently for minimal residual disease (MRD) by flow cytometry (FCM) for leukemia-associated aberrant immune phenotypes and by RQ-PCR for the expression of the Wilms tumor (WT1) gene.
|
24631740 |
2014 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia.
|
16876863 |
2007 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, oncogenic potential of the WT1 gene has been proposed in some human solid tumors and leukemias.
|
17594113 |
2007 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, we developed a WT1 oral cancer vaccine using a recombinant Bifidobacterium displaying WT1 protein, which can efficiently deliver WT1 protein to the gut immune system, and we demonstrated that this oral cancer vaccine had a significant anti-tumor effect in a C1498-WT1 murine leukemia syngeneic tumor model.
|
29048978 |
2018 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Significant levels of WT1 gene were expressed in all leukemia patients and for CML the levels increased as the clinical phase progressed.
|
7949179 |
1994 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subsequent research has shown that the WT1 gene in many other cases acts as an oncogene, most prominently in leukaemia and lung cancer (even though these cancer forms can emerge as a result of many other aetiological factors).
|
25189877 |
2015 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results demonstrate that A1 is a new WT1 target gene involved in both granulocytic differentiation and resistance to cell death, and suggests that these genes might play an important role in the biology of high-risk leukemias.
|
16484585 |
2006 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Wilms' tumor 1 (WT1) gene is overexpressed in leukemia and various types of solid tumor, such as lung and colorectal cancer, and plays an oncogenic role in their tumorigenesis.
|
20180815 |
2010 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The WT1 gene is highly expressed in leukemia and various types of solid tumors, whereas WT1 is a tumor marker convenient for the detection of minimal residual disease of leukemia.
|
20395243 |
2010 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Wilms tumor 1 (WT1) is an intracellular oncogenic transcription factor that is an attractive target for cancer immunotherapy because of its overexpression in a wide range of leukemias and solid tumors, and a low level of expression in normal adult tissues.
|
30045840 |
2018 |